Overview The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus Status: Recruiting Trial end date: 2021-06-30 Target enrollment: Participant gender: Summary This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study in patients with type 2 diabetes mellitus (T2DM). Phase: Phase 2 Details Lead Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd.